NZ580415A - Dosing regimen for (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol - Google Patents

Dosing regimen for (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol

Info

Publication number
NZ580415A
NZ580415A NZ580415A NZ58041508A NZ580415A NZ 580415 A NZ580415 A NZ 580415A NZ 580415 A NZ580415 A NZ 580415A NZ 58041508 A NZ58041508 A NZ 58041508A NZ 580415 A NZ580415 A NZ 580415A
Authority
NZ
New Zealand
Prior art keywords
dose
administration
tapentadol
optional
interval
Prior art date
Application number
NZ580415A
Other languages
English (en)
Inventor
Claudia Lange
Ferdinand Rombout
Original Assignee
Gruenenthal Chemie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38123877&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ580415(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gruenenthal Chemie filed Critical Gruenenthal Chemie
Publication of NZ580415A publication Critical patent/NZ580415A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Adhesive Tapes (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NZ580415A 2007-04-23 2008-04-21 Dosing regimen for (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol NZ580415A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07008218A EP1985292A1 (en) 2007-04-23 2007-04-23 Titration of tapentadol
PCT/EP2008/003178 WO2008128740A1 (en) 2007-04-23 2008-04-21 Titration of tapentadol

Publications (1)

Publication Number Publication Date
NZ580415A true NZ580415A (en) 2012-04-27

Family

ID=38123877

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ580415A NZ580415A (en) 2007-04-23 2008-04-21 Dosing regimen for (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol

Country Status (21)

Country Link
US (4) US20090012180A1 (enExample)
EP (5) EP1985292A1 (enExample)
JP (4) JP5933176B2 (enExample)
KR (3) KR20100017267A (enExample)
CN (1) CN101730530B (enExample)
AT (1) ATE534378T1 (enExample)
AU (1) AU2008241013B2 (enExample)
CA (1) CA2683786C (enExample)
CY (1) CY1112320T1 (enExample)
DK (1) DK2148670T3 (enExample)
ES (1) ES2378255T3 (enExample)
HR (1) HRP20120147T1 (enExample)
IL (1) IL201479A (enExample)
MX (1) MX2009011444A (enExample)
NZ (1) NZ580415A (enExample)
PL (1) PL2148670T3 (enExample)
PT (1) PT2148670E (enExample)
RU (1) RU2472497C2 (enExample)
SI (1) SI2148670T1 (enExample)
WO (1) WO2008128740A1 (enExample)
ZA (1) ZA200907355B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1985292A1 (en) * 2007-04-23 2008-10-29 Grünenthal GmbH Titration of tapentadol
JP6216489B2 (ja) * 2008-10-30 2017-10-18 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 新規の、効力のあるタペンタドール剤形
US8870876B2 (en) * 2009-02-13 2014-10-28 Tarsus Medical Inc. Methods and devices for treating hallux valgus
US8277459B2 (en) 2009-09-25 2012-10-02 Tarsus Medical Inc. Methods and devices for treating a structural bone and joint deformity
US8652141B2 (en) 2010-01-21 2014-02-18 Tarsus Medical Inc. Methods and devices for treating hallux valgus
US20130116333A1 (en) * 2010-05-05 2013-05-09 Ratiopharm Gmbh Solid tapentadol in non-crystalline form
US8696719B2 (en) 2010-06-03 2014-04-15 Tarsus Medical Inc. Methods and devices for treating hallux valgus
HRP20161166T1 (hr) * 2010-06-30 2016-11-04 Grünenthal GmbH Tapentadol za uporabu u liječenju sindroma iritabilnog crijeva
EP3650439B1 (en) * 2010-07-23 2021-02-24 Grünenthal GmbH Salts or co-crystals of 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol
CN101948397A (zh) * 2010-09-07 2011-01-19 天津泰普药品科技发展有限公司 镇痛药他喷他多重要中间体的制备方法
RS54711B1 (sr) * 2011-03-04 2016-08-31 Grünenthal GmbH Parenteralno davanje tapentadola
SI3287123T1 (sl) 2011-03-04 2020-07-31 Gruenenthal Gmbh Vodna farmacevtska formulacija tapentadola za peroralno uporabo
KR101911362B1 (ko) 2011-03-04 2018-10-25 그뤼넨탈 게엠베하 타펜타돌을 함유하는 반고체 수성 약제학적 조성물
PL2694050T3 (pl) * 2011-04-05 2020-03-31 Grünenthal GmbH Tapentadol do stosowania w leczeniu bólu związanego z nerwobólami nerwu trójdzielnego
US20120309841A1 (en) * 2011-04-05 2012-12-06 Gruenenthal Gmbh Method of Inhibiting Chronification of Pain
RS60152B1 (sr) 2011-04-29 2020-05-29 Gruenenthal Gmbh Tapentadol za sprečavanje i lečenje depresije i anksioznosti
WO2014152296A1 (en) * 2013-03-15 2014-09-25 Mallinckrodt Llc Abuse deterrent solid dosage form for immediate release with functional score
EP2845625A1 (en) * 2013-09-04 2015-03-11 Grünenthal GmbH Tapentadol for use in the treatment of fibromyalgia and chronic fatigue syndrome
PT3479823T (pt) 2015-03-27 2020-09-29 Gruenenthal Gmbh Formulação estável para administração parentérica de tapentadol
JP6853791B2 (ja) * 2015-05-26 2021-03-31 テクノファージ， インベスティガサン エ デセンボルビメント エム ビオテクノロジア，エスエー パーキンソン病及び関連する障害の治療における使用のための組成物
WO2017148595A1 (en) * 2016-02-29 2017-09-08 Grünenthal GmbH Titration of cebranopadol
EP3515412B1 (en) 2016-09-23 2025-04-23 Grünenthal GmbH Stable formulation for parenteral administration of tapentadol
AU2021237693A1 (en) 2020-03-16 2022-09-08 Grünenthal GmbH Scored tablet
WO2022194941A1 (en) * 2021-03-17 2022-09-22 Actelion Pharmaceuticals Ltd Pharmaceutical dosage system
US20240238221A1 (en) * 2021-05-07 2024-07-18 Grünenthal GmbH Tapentadol for treating neuropathic pain in covid-19 patients

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4783337A (en) 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
US4612008A (en) * 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US4765989A (en) 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
JPS6327805A (ja) 1986-07-21 1988-02-05 Sumitomo Electric Ind Ltd 光フアイバの接続用部材及びそれを用いた接続方法
DE4426245A1 (de) * 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
US6339105B1 (en) * 1999-10-12 2002-01-15 Ortho-Mcneil Pharmaceutical, Inc. Analgesic regimen
PE20030527A1 (es) 2001-10-24 2003-07-26 Gruenenthal Chemie Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen
MXPA05006334A (es) * 2002-12-13 2005-08-26 Euro Celtique Sa Dosis de buprenorfina transdermica para analgesia.
US7413749B2 (en) * 2003-03-11 2008-08-19 Purdue Pharma L.P. Titration dosing regimen for controlled release tramadol
DE102007019417A1 (de) 2007-04-23 2008-11-13 Grünenthal GmbH Tapentadol zur Schmerzbehandlung bei Arthrose
EP1985292A1 (en) * 2007-04-23 2008-10-29 Grünenthal GmbH Titration of tapentadol

Also Published As

Publication number Publication date
PT2148670E (pt) 2012-01-24
US20170079938A1 (en) 2017-03-23
CA2683786C (en) 2021-10-26
IL201479A0 (en) 2010-05-31
IL201479A (en) 2016-04-21
ZA200907355B (en) 2010-08-25
EP1985292A1 (en) 2008-10-29
US20160074342A1 (en) 2016-03-17
JP2018030864A (ja) 2018-03-01
KR102078999B1 (ko) 2020-02-19
WO2008128740A1 (en) 2008-10-30
ES2378255T3 (es) 2012-04-10
KR20100017267A (ko) 2010-02-16
EP2148670A1 (en) 2010-02-03
CN101730530A (zh) 2010-06-09
ATE534378T1 (de) 2011-12-15
CA2683786A1 (en) 2008-10-30
EP2422778A1 (en) 2012-02-29
US11344512B2 (en) 2022-05-31
US20190290603A1 (en) 2019-09-26
RU2009142940A (ru) 2011-05-27
KR20180004839A (ko) 2018-01-12
WO2008128740A8 (en) 2010-06-17
JP5933176B2 (ja) 2016-06-08
PL2148670T3 (pl) 2012-04-30
EP2148670B1 (en) 2011-11-23
AU2008241013A1 (en) 2008-10-30
EP3603630A1 (en) 2020-02-05
HRP20120147T1 (hr) 2012-03-31
US20090012180A1 (en) 2009-01-08
MX2009011444A (es) 2009-11-05
CN101730530B (zh) 2013-10-23
EP3143993A1 (en) 2017-03-22
SI2148670T1 (sl) 2012-03-30
JP2019131598A (ja) 2019-08-08
HK1140940A1 (en) 2010-10-29
AU2008241013B2 (en) 2013-06-20
DK2148670T3 (da) 2012-03-12
KR20150027840A (ko) 2015-03-12
CY1112320T1 (el) 2015-12-09
JP2010531296A (ja) 2010-09-24
RU2472497C2 (ru) 2013-01-20
JP2016128468A (ja) 2016-07-14

Similar Documents

Publication Publication Date Title
US11344512B2 (en) Titration of tapentadol
US20200061003A1 (en) Acamprosate formulations, methods of using the same, and combinations comprising the same
KR101632858B1 (ko) 파킨슨병의 치료에 있어서 오피오이드 효능제와 오피오이드 길항제의 조합물
US20090023744A1 (en) Combination therapy for depression
TW202317101A (zh) 治療抑鬱狀態之方法
US20030190351A1 (en) Extended release venlafaxine formulations
HK1233916A1 (en) Titration of tapentadol
US20080058345A1 (en) Combination Therapy with Mecamylamine for the Treatment of Mood Disorders
HK1140940B (en) Titration of tapentadol

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 APR 2016 BY CPA GLOBAL

Effective date: 20150306

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 APR 2017 BY CPA GLOBAL

Effective date: 20160311

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 APR 2018 BY CPA GLOBAL

Effective date: 20170311

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 APR 2019 BY CPA GLOBAL

Effective date: 20180309

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 APR 2020 BY CPA GLOBAL

Effective date: 20190307

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 APR 2021 BY CPA GLOBAL

Effective date: 20200306

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 APR 2022 BY CPA GLOBAL

Effective date: 20210305

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 APR 2023 BY CPA GLOBAL

Effective date: 20220310

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 APR 2024 BY CPA GLOBAL

Effective date: 20230309

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 APR 2025 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20240308

LAPS Patent lapsed